Revenue ($USD) : $6,004,800,000
R&D spend : $1,071,800,000
Employees : 20,000
Fiscal year end : 12/31/2023
CEO : Bernard Zovighian

www.edwards.com

Edwards Lifesciences won FDA approval of its Evoque tricuspid valve replacement system in February 2024 and then announced a series of M&A deals. First, it said in June it would sell its Critical Care business (which it previously planned to spin off) to BD for $4.2 billion. Edwards then announced plans to spend $1.2 billion to buy JenaValve Technology and Endotronix. The JenaValve Trilogy Heart Valve System for aortic regurgitation could win FDA approval in late 2025, while the FDA already approved the Endotronix Cordella implantable pulmonary artery pressure sensor in June, with a CMS national coverage determination slated for early 2025. Edwards is also acquiring mitral valve company Innovalve for $300 million and entered into a series of licensing and development deals with Affluent Medical involving Affluent’s Kalios adjustable mitral annulus and mitral valve technology. –CN